header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-151106-1
Fish name: gz32Tg; nz50Tg
Genotype: gz32Tg; nz50Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gz32Tg; nz50Tg
No data available
GENE EXPRESSION
Gene expression in gz32Tg; nz50Tg
PHENOTYPE
Phenotype in gz32Tg; nz50Tg
Phenotype Conditions Figures
female organism neutrophil mpx expression decreased amount, abnormal chemical treatment: cortisol, chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
female organism neutrophil lyz expression decreased amount, abnormal chemical treatment: cortisol, chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
female organism neutrophil il12a expression decreased amount, abnormal chemical treatment: cortisol, chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
female organism neutrophil lyz expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
female organism neutrophil csf1a expression increased amount, abnormal chemical treatment: cortisol, chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
female organism neutrophil csf1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
female organism neutrophil il10 expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
female organism neutrophil increased amount, abnormal chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
female organism neutrophil il10 expression increased amount, abnormal chemical treatment: cortisol, chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
female organism neutrophil mpx expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
female organism neutrophil il12a expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
female organism neutrophil increased amount, exacerbated chemical treatment: cortisol, chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
liver increased size, abnormal chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate Fig. 2 with image from Yan et al., 2015
liver increased size, abnormal chemical treatment: lipopolysaccharide, chemical treatment: doxycycline monohydrate Fig. 2 with image from Yan et al., 2015
liver increased size, abnormal chemical treatment: doxycycline monohydrate Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 8 with image from Yan et al., 2015
liver neutrophil increased amount, abnormal chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate Fig. 2 with image from Yan et al., 2015
liver neutrophil increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 3Fig. 5 from Yan et al., 2017
liver neutrophil increased amount, abnormal chemical treatment: lipopolysaccharide, chemical treatment: doxycycline monohydrate Fig. 2 with image from Yan et al., 2015
liver neutrophil increased amount, abnormal chemical treatment: doxycycline monohydrate Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 8 with image from Yan et al., 2015
male organism neutrophil lyz expression amount, ameliorated chemical treatment: mifepristone Fig. 5 from Yan et al., 2017
male organism neutrophil mpx expression amount, ameliorated chemical treatment: mifepristone Fig. 5 from Yan et al., 2017
male organism neutrophil il12a expression amount, ameliorated chemical treatment: mifepristone Fig. 5 from Yan et al., 2017
male organism neutrophil il10 expression amount, ameliorated chemical treatment: mifepristone Fig. 5 from Yan et al., 2017
male organism neutrophil csf1a expression amount, ameliorated chemical treatment: mifepristone Fig. 5 from Yan et al., 2017
male organism neutrophil il12a expression decreased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
male organism neutrophil lyz expression decreased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
male organism neutrophil mpx expression decreased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
male organism neutrophil il10 expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
male organism neutrophil increased amount, abnormal chemical treatment: doxycycline Fig. 5 from Yan et al., 2017
male organism neutrophil csf1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 2Fig. 5 from Yan et al., 2017
male organism neutrophil increased amount, ameliorated chemical treatment: mifepristone Fig. 5 from Yan et al., 2017
neutrophil il12a expression decreased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil lyz expression decreased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil tnfa expression decreased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil mpx expression decreased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil csf1a expression increased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil il1b expression increased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil nfkb2 expression increased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil cxcl18b expression increased amount, abnormal chemical treatment: doxycycline Fig. 3 from Yan et al., 2017
neutrophil nucleus morphology, abnormal chemical treatment: doxycycline monohydrate Fig. 4 with image from Yan et al., 2015

CITATIONS  (2)